BioNova Pharmaceuticals (Shanghai) Ltd.
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2018-12-25
- Employees
- 11
- Market Cap
- -
- Website
- http://www.bionovapharma.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
The Effect of Food on the Pharmacokinetics of BN104 Tablets
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- BioNova Pharmaceuticals (Shanghai) LTD.
- Target Recruit Count
- 16
- Registration Number
- NCT06724549
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study of BN104 in the Treatment of Acute Leukemia
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- BioNova Pharmaceuticals (Shanghai) LTD.
- Target Recruit Count
- 90
- Registration Number
- NCT06052813
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, China
Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
- Conditions
- B-cell LymphomaDiffuse Large B Cell LymphomaMantle Cell LymphomaNon Hodgkin LymphomaFollicular Lymphoma
- Interventions
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- BioNova Pharmaceuticals (Shanghai) LTD.
- Target Recruit Count
- 9
- Registration Number
- NCT05611853
- Locations
- 🇨🇳
The first affiliated hospital, Zhejiang Unviersity school of medicine, Hangzhou, China
🇨🇳The First Affiliated School of Guangxi Medical University, Nanning, China
🇨🇳Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, Shanghai, China
A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- BioNova Pharmaceuticals (Shanghai) LTD.
- Registration Number
- NCT05365100
- Locations
- 🇨🇳
ZhuJiang Hospital of Southern Medical University, Guangzhou, China
🇨🇳The First Affiliated School of Guangxi Medical University, Nanning, China
🇨🇳Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, Shanghai, China
Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- BioNova Pharmaceuticals (Shanghai) LTD.
- Target Recruit Count
- 30
- Registration Number
- NCT04930562
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳Xinqiao Hospital, Army Medical University, Chongqing, China
🇨🇳Guangzhou First People's Hospital, Guangzhou, China